

Pharmacy Services

(800) 522-0114, option 4

March 2, 2016

Dear SoonerCare Provider,

The Oklahoma Health Care Authority is engaged in an effort to improve cost effective utilization of tetracycline and fluoroquinolone antibiotics by our members. The purpose of this fax is to provide updates regarding tetracycline and fluoroquinolone antibiotic coverage.

Effective March 15th, 2016, the following changes will be made to the tetracycline and fluoroquinolone antibiotics category:

1. Prior authorization will no longer be required for **doxycycline monohydrate immediate-release capsules 50mg and 100mg strengths** (75mg capsules, 150mg capsules, and 150mg tablets will require prior authorization).
2. **Tetracycline 250mg and 500mg capsules** will require a prior authorization.
 - a. Approval requires a patient-specific, clinically significant reason why the member requires tetracycline and cannot use doxycycline or minocycline capsules and/or other cost effective therapeutic equivalent medication(s).
3. **Minocycline immediate-release tablets** will require a prior authorization.
 - a. Approval requires a patient-specific, clinically significant reason why the member requires the immediate-release tablet formulation and cannot use the immediate-release capsule formulation and/or other cost effective therapeutic equivalent medication(s).
4. An age restriction of six years and younger for **levofloxacin 25mg/mL oral solution, ciprofloxacin 250mg/mL oral suspension, and ciprofloxacin 500mg/mL oral suspension** will apply.
 - a. Members older than six years of age would require a patient-specific, clinically significant reason why the oral tablet formulations cannot be used.
5. **Ofloxacin 400mg and moxifloxacin 400mg tablets** will require a prior authorization.
 - a. Approval requires a patient-specific, clinically significant reason why the member cannot use ciprofloxacin tablets, levofloxacin tablets, and/or other cost effective therapeutic equivalent medication(s).
6. **Ciprofloxacin 100mg tablets** will require a prior authorization.
 - a. Approval requires a patient-specific, clinically significant reason why the member cannot use alternative strengths of ciprofloxacin tablets or levofloxacin tablets and/or other cost effective therapeutic equivalent medication(s).
7. **Ciprofloxacin 500mg and 1000mg extended-release tablets** will require a prior authorization.
 - a. Approval requires a patient-specific, clinically significant reason why the member cannot use the immediate-release formulation of ciprofloxacin tablets, levofloxacin tablets, and/or other cost effective therapeutic equivalent medication(s).

Thank you for the services you provide to Oklahomans insured by SoonerCare!